STOCK TITAN

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Exagen Inc. will release its financial results for Q3 2023 on November 13, 2023. The conference call to review the results will be hosted by the President and CEO, John Aballi, and the CFO, Kamal Adawi. Interested parties can access the call via dial-in or webcast. A replay of the call will be available until November 27, 2023.
Positive
  • None.
Negative
  • None.

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Monday, November 27, 2023, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13741926. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

CONTACTS:

Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com


Exagen will release its financial results for Q3 2023 on November 13, 2023.

The conference call to review the results will be hosted by Exagen's President and CEO, John Aballi, and CFO, Kamal Adawi.

Interested parties can access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). They can also access the call via webcast using the link posted on the Exagen investor relations website at investors.exagen.com.

The replay of the conference call will be available until November 27, 2023.

Interested parties can access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13741926. They can also access a recording of the webcast using the link on the Exagen investor relations website approximately one hour after the call concludes.
Exagen Inc

NASDAQ:XGN

XGN Rankings

XGN Latest News

XGN Stock Data

Dental Laboratories
Manufacturing
Link
Health Services, Medical/Nursing Services, Manufacturing, Dental Laboratories
US
Vista

About XGN

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.